Micrima

Half a million women a year die of breast cancer and yet if detected early enough it’s one of the most survivable cancers. Micrima believe the key is early detection.

This requires a method of imaging that is radiation free and comfortable for women so screening can be carried out frequently, from a young age, that women are willing to attend. Micrima have developed the CE marked MARIA® system which uses radio-waves and involves no breast compression.

Today it’s being used in symptomatic clinics as an adjunct to other imaging modalities to reduce the chances of missing a cancer.

In clinical trials it has proven effective at cancer detection particularly in dense tissue, which also occurs most frequently, but not exclusively in younger women.

Further development of MARIA® is ongoing using the clinical data we have, as a result of multiple trials, with machine learning we are further improving our detection and giving an indicator of likelihood of a finding being cancer, (A classifier). This is a significant step forward in breast imaging.

To find out more about this technology contact us on info@micrima.com or check out Micrima.com for the latest information and to sign up to receive our newsletter.

Event Diary

Following the 2017 Naylor Report into NHS estates, it has been estimated that estate upkeep costs have reached approximately £10bn in annual funding for 2019/2020.

More recently, ERIC (Estates Returns Information Collection) data collection has contained some deeply alarming news about the condition of NHS buildings and equipment.

Supplier Profiles